



February 8, 2024

To whom it may concern

Company: Teijin Limited
 Representative: Akimoto Uchikawa, President and CEO
 Stock code: 3401 (Prime Market, Tokyo Stock Exchange)
 Contact: Naoki Hamashima, General Manager,
 Investor and Public Relations Department
 TEL: +81-3-3506-4395

Notice Regarding the Revision of Financial Forecasts

Teijin Limited (hereinafter, the “Company”) hereby announces that, based on its recent performance, it has revised its consolidated financial forecasts for the fiscal year ending March 2024 (April 1, 2023, to March 31, 2024) from the values announced on November 6, 2023.

1. Revision of consolidated financial forecasts for the fiscal year ending March 31, 2024

	Net sales	Operating income	Ordinary income	Profit attributable to owners of parent	Earnings per share
	million yen	million yen	million yen	million yen	yen
Previously announced forecast (A)	1,030,000	35,000	31,000	13,000	67.55
Revised forecast (B)	1,030,000	18,000	19,000	8,000	41.57
Change (B – A)	0	-17,000	-12,000	-5,000	—
Percent change (%)	0.0%	-48.6%	-38.7%	-38.5%	—
(Ref.) Results for the previous fiscal year (FY2022)	1,018,751	12,863	9,100	-17,695	-92.04

[Reasons for the revision of the financial forecasts]

We have decided to revise our operating income forecast downward from the previously announced value as shown above mainly due to the one-off lump-sum contract fee for in-licensed pharmaceutical products^{*1} in the Healthcare segment and several factors in the Materials segment, including weaker demand and inventory adjustment in the supply chain for products for several applications and unachieved operational stabilization caused by recurrence of equipment breakdowns in the composites business. We have also decided to revise downward our forecasts for ordinary income and profit attributable to owners of parent as shown above due to the significant decrease in operating income despite non-operating income that, we recorded as non-operating income regarding compensation for the partial settlement of a suit in which one of our unconsolidated subsidiaries was involved as

announced separately today^{*2}.

We have made no change to our dividend forecast.

*1 For details, refer to the “Notice Concerning a Decision on the Licensing Agreement related to the Three Hormone Therapy Drugs for Rare Endocrine Diseases” issued on November 29, 2023.

*2 For details, refer to the “Notice Regarding Recording of Non-operating Income (Equity in Earnings of Affiliates) due to Partial Resolution of Litigation Involving an Unconsolidated Subsidiary” issued today.

- End -